1 min read
Add as a preferred source on Google

GT Biopharma Posts $3.5 Million Q3 Loss, Projects Runway Into Q3 2027

It had about $10 million in cash on Sept. 30, 2026, after posting net income of $8.3 million in the year-earlier quarter.

A glass vial and coin rest on a short stainless-steel track / TokenPost.ai
A glass vial and coin rest on a short stainless-steel track / TokenPost.ai

GT Biopharma, Inc. posted a net loss of about $3.5 million for the third quarter of 2026, compared with net income of $8.3 million in the same quarter a year earlier.

The company had about $10 million in cash as of Sept. 30, 2026. It expects that balance to provide a cash runway into the third quarter of 2027.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…